---
edit_url: "https://github.com/dhis2-metadata/TB_AGG/blob/master/docs/release_note.md"
revision_date: '2024-01-02'
tags:
- Implementace
---

# Release Note { #tb-agg-release-note }

## 2.0.0 { #200 } 

This is a major new release of the TB metadata and system design for integrating routine tuberculosis data into national HMIS for analysis. This version is aligned with the latest WHO strategic information guidelines for tuberculosis programmes (2023).

The changes affect the notification and outcomes for first and second-line treatment and the household contacts of the confirmed TB cases.

### New Content { #new-content } 

Metadata changes primarily affect the notification and outcomes for first and second-line treatment, as well as household contacts of confirmed TB cases. 

* **Notification and Outcomes**

  The main changes to the datasets TB - Case notification, TB - Case notification (additional), TB - Treatment outcomes, and TB - Treatment outcomes (second line) datasets include:
  Updated dataset name dataset name for additional yearly notifications. This dataset is considered an annual extension of the routine core quarterly reported information and is therefore called “additional”.

* **TB - Case notification (additional)** (previously called ‘TB - RR/MDR case detection and treatment’

   Updated metadata (new, older and legacy) names to conform with updated WHO nomenclature for:
      - **Recurrent** cases (previously referred to as ‘relapsed’)
      - **Re-registered** cases (previously referred to as ‘retreated’)
      - **New episode** cases (previously referred to as ‘new or relapse’)

   Updated data elements to reflect the new guidelines on disaggregation, such as
      - Data Elements for Extrapulmonary, bacteriologically confirmed or clinically diagnosed  no longer require a disaggregation by treatment history
      - Additional age disaggregations for TB cases
      - Resistance monitoring classifications (e.g. Isoniazid, fluoroquinolones and bedaquiline susceptibility testing)
      - Treatment history: Lab confirmed RR/MDR-TB now disaggregated by previous treatment history
      - Treatment regimen: DR-TB cohorts are now defined in terms of their regimen length and content

* **TB Prevention - Household (HH) contacts**

   Split previous dataset into two new datasets to ensure precise calculations derived from specific cohorts and analysis periods; and allows for streamlined aggregation of data sourced from the Household Contacts Investigation tracker:
      - Notifications of HH contacts
      - Tuberculosis Preventive Treatment (TPT) outcomes

* Datové prvky
  Revised disaggregation no longer includes the HIV status of the contacts, but maintains age disaggregation (under or over 5 years old).

All the changes to the metadata are also reflected in the indicators employed for the analysis of the TB - Data Quality dashboard.

## 1.5.0 { #150 } 

The Data Quality (DQ) dashboard and guide are added to the TB HMIS toolkit.

## 1.4.1 { #141 } 

French translations were added to all package components.

## 1.4.0 { #140 } 

Revised package including a new component: Laboratory data set and dashboard.

## 1.1.1 { #111 } 

* Zahrnutá skupina uživatelů `UKWx4jJcrKt` "TB data capture", která má práva pro sběr dat pro všechny objekty, které lze sdílet (pouze v kompletním balíčku)
* Changed public access sharing to metadata view and data view.
* Odstraněn ovládací panel `o2Wg6pXAN6X` "TB2.Notifications (rates)" a související graf `gTcOAYjw4CQ`, kontingenční tabulka `HCmjOlNONzQ` a mapa `z4FMNqKG4gl`.
* Aktualizované rozložení ovládacího panelu pro použití s novou aplikací ovládacího panelu (od DHIS 2.29 a vyšší)
* Aktualizovaná období v oblíbených, včetně dat do Q2 2019 včetně (kde je to relevantní)
* Drobné změny rozložení kontingenčních tabulek `hQ1ksBSIpQr` a` n6ZXdAl1sfD`
* Aktualizovány názvy oblíbených map
    * Používání vestavěné podpory překladu pro francouzská jména místo anglických a francouzských jmen.
    * Renamed maps `Eq9lKUQOykM` and `HFi8Oy2fFdJ` from TBm_3.8_... to TBm_3.7_...
    * Přejmenované mapy `b6VznqkP4Hc` a `oA74TkHOKnX` na "TBc_3.5_Ratio případů TBC ve věku 0-4: 5-14 let u nových a relapsů" a "TBc_3.5_Ratio případů TBC ve věku 0-4: 5-14 let u nových a relapsů (roční)“
* Opravený graf `TfeoSE7Ha8F`, změna dimenze dat ze skupiny možností kategorie nastavena z „Pohlaví“ na „Pohlaví (s neznámým)“
* Opravený jmenovatel indikátoru `whkj4kr4ghD`, by měl být `#{hKTgk1mG2qn} + #{PdhQ1JCS2ij} + #{M6JHtLJJ34t} + #{KZ7rMA7BqcQ} + #{l4TyT04yP8f} + #{NYxehRdsQx3} +#{QNFhsj0fOxK} + #{Nv1RGi4eI7F} + #{NJaeD9Xia7x} + #{KhCB35MHs9A}`
* Změněn popis indikátoru `p18w24U0caC`
* Změněn název, shortName, kód a popis indikátoru `VLtzufVWnHc`
* Fixed 3 validation rules with incorrect formulas:
    * `bDjCyRMtkHO` - nový plicní stěr pozitivní
    * `VhVCSKuqraP`- nový plicní stěr negativní / stěr neznámý / stěr nebyl proveden
    * `hZveAwRhLRh` - nové mimoplicní případy
* Přejmenován graf `Fw0CsA5Dpvf` (z "TBc_4.3c_výstupy léčby pro DR-TB (%) (roční)" na "TBc_5.5_výstupy léčby pro DR-TB (%) (roční)) a přidán na ovládací panel `xJXvUOEhnE9` ("TB5. DR-TB (roční)").

### Version 1.1.0 { #version-110 } 
* Přidána tři ověřovací pravidla pro sekci TB/HIV souboru dat „Výsledky léčby TBC“:
    * `hXd2GANq20y` -"Testování na TB/HIV (podle času výsledku)"
    * `zANh0v8Sbr1`- "HIV pozitivní TBC pacienti na preventivní terapii kotrimoxazolem (CPT) (podle času výstupu)"
    * `EG3H3WrJnKe` - "HIV-positive TB patients on antiretroviral therapy (ART) (by time of outcome)"
* Opravena tři ověřovací pravidla:
    * `puOMC36U2ad` - "HIV pozitivní pacienti s TBC na antiretrovirové terapii (ART)"
    * `MWDQUNd4sZE`- "HIV pozitivní TBC pacienti na preventivní terapii kotrimoxazolem (CPT)"
    * `TV3eW5zYLep` - "Testování na TB / HIV"
* Přidány dvě oblíbené položky kontingenční tabulky pouze pro dokončení balíčku (tyto nejsou součástí žádných ovládacích panelů):
    * `StXxQoaz26k` - "TBt_0.1_Notifications_all data elements_annual"
    * `dQxhOVtwwK8` - "TBt_0.2_Treatment outcomes_all data elements_annual"
* Opraveny dva grafy, kde byl výběr indikátoru prázdný. Oba grafy by měly mít jako data vybrán indikátor `VLtzufVWnHc` "TB - nové a relapsové případy TBC podle věku a pohlaví“ a dimenze dat by měla být nastavena na "filtr":
    *  `TfeoSE7Ha8F` - "TBc_1.2_Nové a relapsové případy podle věkové skupiny a pohlaví"
    *  `VBUUGBP8RFn` - "TBc_1.2_Nové a relapsové případy podle věkové skupiny a pohlaví (roční)"
* Opraveno několik indikátorů, včetně názvů, popisů a vzorců:

<table>
    <tr>
        <th>ID</th>
        <th>Name</th>
        <th>Modified property</th>
        <th>Old value</th>
        <th>New value</th>
    </tr>
    <tr>
        <td>lRAKLRVIMgp</td>
        <td>TB - Notified TB cases (all cases, all forms)</td>
        <td>code</td>
        <td>TB_C_NEWINC_ALL</td>
        <td>TB_C_NOTIFIED</td>
    </tr>
    <tr>
        <td>YWTs6xdTRFF</td>
        <td>TB - Notified TB cases (new and relapse, all forms)</td>
        <td>code</td>
        <td>TB_C_NEWINC_NEWREL</td>
        <td>TB_C_NEWINC</td>
    </tr>
    <tr>
        <td>fBwmklJ0VNp</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 0-4 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged under 0-4 (new and relapse only)</td>
        <td>Number of TB cases aged 0-4 (new and relapse only)</td>
    </tr>
    <tr>
        <td>ExXsF5qlzdc</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 15-24 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged 15-24 (new and relapse only)</td>
        <td>Number of TB cases aged 15-24 (new and relapse only)</td>
    </tr>
    <tr>
        <td>zyyolGvDOLQ</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 25-34 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged 25-34 (new and relapse only)</td>
        <td>Number of TB cases aged 25-34 (new and relapse only)</td>
    </tr>
    <tr>
        <td>v7cZx5SUBXP</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 35-44 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged 35-44 (new and relapse only)</td>
        <td>Number of TB cases aged 35-44 (new and relapse only)</td>
    </tr>
    <tr>
        <td>rv14EhkmZof</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 45-54 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged 45-54 (new and relapse only)</td>
        <td>Number of TB cases aged 45-54 (new and relapse only)</td>
    </tr>
    <tr>
        <td>zw1DhQYN9mb</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 5-14 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged 5-14 (new and relapse only)</td>
        <td>Number of TB cases aged 5-14 (new and relapse only)</td>
    </tr>
    <tr>
        <td>TV1Qm6X0ILb</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 55-64 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged 55-64 (new and relapse only)</td>
        <td>Number of TB cases aged 55-64 (new and relapse only)</td>
    </tr>
    <tr>
        <td>vwRyMhcuZDh</td>
        <td>TB - Notified TB cases (new and relapse, all forms) aged 65+ (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged 65+ (new and relapse only)</td>
        <td>Number of TB cases aged 65+ (new and relapse only)</td>
    </tr>
    <tr>
        <td>aPT4OksC5z7</td>
        <td>TB - Notified TB cases (new and relapse, all forms) children aged 0-14 (%)</td>
        <td>numeratorDescription</td>
        <td>Number of children aged under 15</td>
        <td>Number of TB cases aged 0-15 (new and relapse only)</td>
    </tr>
    <tr>
        <td>JCs9GgdcC7d</td>
        <td>TB - Notified TB cases (new and relapse, pulmonary clinically diagnosed)</td>
        <td>code</td>
        <td>TB_C_NEWINC_CLINCONF</td>
        <td>TB_C_NEWINC_CLINDX</td>
    </tr>
    <tr>
        <td>JCs9GgdcC7d</td>
        <td>TB - Notified TB cases (new and relapse, pulmonary clinically diagnosed)</td>
        <td>numeratorDescription</td>
        <td>Pulm bact confirmed new and relapse and history unknown</td>
        <td>Pulmonary clinically diagnosed new and relapse and history unknown</td>
    </tr>
    <tr>
        <td>JCs9GgdcC7d</td>
        <td>TB - Notified TB cases (new and relapse, pulmonary clinically diagnosed)</td>
        <td>numerator</td>
        <td>#{voLCYElGAjX} + #{qlkxnlC6dzU} + #{NYxehRdsQx3} + #{EGlb6CP7czB}"</td>
        <td>#{voLCYElGAjX} + #{qlkxnlC6dzU} + #{NYxehRdsQx3} + #{EGlb6CP7czB}+ #{v2qRhkUmjlV} + #{XLV3S8QL8jV} + #{PRB6dolaxC4}</td>
    </tr>
    <tr>
        <td>VcwgKNqXO9n</td>
        <td>TB - Ratio of TB cases aged 0-4:5-14 (new and relapse, all forms)</td>
        <td>numeratorDescription</td>
        <td>Cases aged 0-4</td>
        <td>Number of TB cases aged 0-4 (new and relapse, all forms)</td>
    </tr>
    <tr>
        <td>VcwgKNqXO9n</td>
        <td>TB - Ratio of TB cases aged 0-4:5-14 (new and relapse, all forms)</td>
        <td>denominatorDescription</td>
        <td>Cases in children aged 5-14</td>
        <td>Number of TB cases aged 5-14 (new and relapse, all forms)</td>
    </tr>
    <tr>
        <td>cX7gRvEV6kK</td>
        <td>TB - TB cases tested for susceptibility to rifampicin (%)</td>
        <td>description</td>
        <td>All TB cases tested for susceptibility to rifampicin - RR-TB(%)</td>
        <td>All TB cases tested for susceptibility to rifampicin (RR-TB) as a percentage of all TB cases notified</td>
    </tr>
    <tr>
        <td>Fyx8nuRcxja</td>
        <td>TB - TB cases tested for susceptibility to rifampicin (new) (%)</td>
        <td>description</td>
        <td>New TB cases tested for susceptibility to rifampicin - RR-TB(%)</td>
        <td>New TB cases tested for susceptibility to rifampicin (RR-TB) as a percentage of all new TB cases notified</td>
    </tr>
    <tr>
        <td>Fyx8nuRcxja</td>
        <td>TB - TB cases tested for susceptibility to rifampicin (new) (%)</td>
        <td>denominatorDescription</td>
        <td>Total notified</td>
        <td>All new TB cases notified (excluding the cases with unknown treatment history)</td>
    </tr>
    <tr>
        <td>Fyx8nuRcxja</td>
        <td>TB - TB cases tested for susceptibility to rifampicin (new) (%)</td>
        <td>denominator</td>
        <td>#{wadYJEcT9yh} + #{voLCYElGAjX} + #{v2qRhkUmjlV} + #{ZiF0ngznP1Z} + #{XLV3S8QL8jV} + #{hKTgk1mG2qn} + #{PdhQ1JCS2ij} + #{M6JHtLJJ34t} + #{KZ7rMA7BqcQ} + #{PRB6dolaxC4} + #{Orjo9ewlU9Z} + #{qlkxnlC6dzU} + #{l4TyT04yP8f} + #{NYxehRdsQx3} +#{QNFhsj0fOxK} + #{Nv1RGi4eI7F} + #{NJaeD9Xia7x} + #{KhCB35MHs9A} + #{lgKh8oeoKVj} + #{EGlb6CP7czB} + #{Q5KSbP9ZzHQ}</td>
        <td>#{wadYJEcT9yh} + #{voLCYElGAjX} + #{v2qRhkUmjlV} + #{ZiF0ngznP1Z} + #{XLV3S8QL8jV} + #{Orjo9ewlU9Z} + #{qlkxnlC6dzU}</td>
    </tr>
    <tr>
        <td>whkj4kr4ghD</td>
        <td>TB - TB cases tested for susceptibility to rifampicin (previously treated) (%)</td>
        <td>description</td>
        <td>Previously treated TB cases (including relapses) tested for susceptibility to rifampicin - RR-TB (%)</td>
        <td>Previously treated TB cases (including relapses) tested for susceptibility to rifampicin (RR-TB) as a percentage of all previously treated (including relapses) TB cases notified</td>
    </tr>
    <tr>
        <td>whkj4kr4ghD</td>
        <td>TB - TB cases tested for susceptibility to rifampicin (previously treated) (%)</td>
        <td>denominatorDescription</td>
        <td>Total notified</td>
        <td>All previously treated (including relapses) TB cases notified</td>
    </tr>
    <tr>
        <td>whkj4kr4ghD</td>
        <td>TB - TB cases tested for susceptibility to rifampicin (previously treated) (%)</td>
        <td>denominator</td>
        <td>#{wadYJEcT9yh} + #{voLCYElGAjX} + #{v2qRhkUmjlV} + #{ZiF0ngznP1Z} + #{XLV3S8QL8jV} + #{hKTgk1mG2qn} + #{PdhQ1JCS2ij} + #{M6JHtLJJ34t} + #{KZ7rMA7BqcQ} + #{PRB6dolaxC4} + #{Orjo9ewlU9Z} + #{qlkxnlC6dzU} + #{l4TyT04yP8f} + #{NYxehRdsQx3} +#{QNFhsj0fOxK} + #{Nv1RGi4eI7F} + #{NJaeD9Xia7x} + #{KhCB35MHs9A} + #{lgKh8oeoKVj} + #{EGlb6CP7czB} + #{Q5KSbP9ZzHQ}</td>
        <td>#{hKTgk1mG2qn} + #{PdhQ1JCS2ij} + #{M6JHtLJJ34t} + #{KZ7rMA7BqcQ} + #{PRB6dolaxC4} + #{Orjo9ewlU9Z} + #{qlkxnlC6dzU} + #{l4TyT04yP8f} + #{NYxehRdsQx3} +#{QNFhsj0fOxK} + #{Nv1RGi4eI7F} + #{NJaeD9Xia7x} + #{KhCB35MHs9A}</td>
    </tr>
    <tr>
        <td>WWephINt8ga</td>
        <td>TB - TB notification rate (all cases, all forms) per 100 000 population</td>
        <td>code</td>
        <td>TB_C_ALLINC_100K</td>
        <td>TB_C_NOTIFIED_100K</td>
    </tr>
    <tr>
        <td>o7QoPpjWR9h</td>
        <td>TB - TB notification rate (new and relapse, pulmonary clinically diagnosed) per 100 000 population</td>
        <td>code</td>
        <td>TB_C_NEWINC_CLINDIAG_100K</td>
        <td>TB_C_NEWINC_CLINDX_100K</td>
    </tr>
    <tr>
        <td>o7QoPpjWR9h</td>
        <td>TB - TB notification rate (new and relapse, pulmonary clinically diagnosed) per 100 000 population</td>
        <td>numerator</td>
        <td>#{voLCYElGAjX}+ #{v2qRhkUmjlV}+#{XLV3S8QL8jV}+#{PRB6dolaxC4}+#{qlkxnlC6dzU}+#{NYxehRdsQx3}+#{NJaeD9Xia7x}+ #{EGlb6CP7czB}</td>
        <td>#{voLCYElGAjX} + #{v2qRhkUmjlV} + #{XLV3S8QL8jV} + #{PRB6dolaxC4} + #{qlkxnlC6dzU} + #{NYxehRdsQx3} + #{EGlb6CP7czB}</td>
    </tr>
    <tr>
        <td>SPJLukKxHaj</td>
        <td>TB - TB treatment success rate (all DS and DR-TB) (%)</td>
        <td>description</td>
        <td>Number of all DS+DR TB cases who were successfully treated (cured or who completed their treatment) as a percentage of the total cohort of all DS+DR TB cases registered, excluding cases moved to second-line treatment</td>
        <td>Number of all DS+DR TB cases who were successfully treated (cured or who completed their treatment) as a percentage of the total cohort of all DS+DR TB cases registered.</td>
    </tr>
</table>

* Přidány indikátory, grafy a mapy (specifikovány níže), které by měly být považovány za „doplňkové“, a poskytují alternativní výstupy, které mohou být za určitých okolností užitečné pro analýzu historických dat. Zejména poskytují vizualizace pro alternativní věkové rozčlenění používané některými zeměmi dříve:
<table>
    <tr>
        <th>Type</th>
        <th>ID</th>
        <th>Name</th>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>PgU1N0PfAwN</td>
        <td>TB - Notified TB cases (new, pulmonary smear positive) by age group and sex</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>SrgAuZUkqHh</td>
        <td>TB - TB cases tested for HIV or with known HIV status - all cases (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>HBkfpoEMWna</td>
        <td>TB - Notified TB cases (new, all forms) aged 55-64 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>eIG3AwbOY4k</td>
        <td>TB - Notified TB cases (new, all forms) aged 65+ (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>trwSfpxsWcb</td>
        <td>TB - Notified TB cases (new, all forms) aged 45-54 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>GjDECoLvM1z</td>
        <td>TB - Notified TB cases (new, all forms) aged 5-14 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>cT1tyz6k18X</td>
        <td>TB - Notified TB cases (new, all forms) aged 35-44 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>B1HKzq73wJr</td>
        <td>TB - Notified TB cases (new, all forms) aged 15-24 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>KlETO0IOKtI</td>
        <td>TB - Notified TB cases (new, all forms) aged 25-34 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>aPfDXoI0tPS</td>
        <td>TB - Notified TB cases (new, all forms) aged 0-14 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>jU1JpPt2T62</td>
        <td>TB - Notified TB cases (new, all forms) aged 0-4 (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>aArkaKMHNhw</td>
        <td>TB - Not evaluated (new and relapse pulmonary bacteriologically confirmed DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>N7OZj7DONas</td>
        <td>TB - Not evaluated (previously treated DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>xlmDFjsyuiS</td>
        <td>TB - Not evaluated (all DR-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>HSLNfDLCbUc</td>
        <td>TB - Not evaluated (all DS-TB/HIV cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>c5yG2hQbSWF</td>
        <td>TB - Lost to follow-up (previously treated DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>w3CiHTdwV4j</td>
        <td>TB - Lost to follow-up (all DS-TB/HIV cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>NNwvy3Ym6vj</td>
        <td>TB - Lost to follow-up (new and relapse pulmonary bacteriologically confirmed DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>nhoEcbYl2hU</td>
        <td>TB - Failed (previously treated DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>Tm4N8CLJM9I</td>
        <td>TB - Lost to follow-up (all DR-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>m0VAZ280hFd</td>
        <td>TB - Failed (all DS-TB/HIV cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>XjyUl0Jmjbj</td>
        <td>TB - Failed (new and relapse pulmonary bacteriologically confirmed DS-TB cases)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>wTmoLwBYFa8</td>
        <td>TB - Died (previously treated DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>P6wlyWUyJHp</td>
        <td>TB - Failed (all DR-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>gHZcDFFvq5x</td>
        <td>TB - Died (new and relapse pulmonary bacteriologically confirmed DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>RlFZHghqtq7</td>
        <td>TB - Died (all DS-TB/HIV cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>c6ju86FLKzU</td>
        <td>TB - Died (all DR-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>WCE27g52nBt</td>
        <td>TB - Cured (new and relapse pulmonary bacteriologically confirmed DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>OuSWXCijKks</td>
        <td>TB - Cured (previously treated DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>VTNrh2DfO91</td>
        <td>TB - Cured (all DS-TB/HIV cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>JfrM1j1pYhc</td>
        <td>TB - Cured (all DR-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>HBB4o9xQScX</td>
        <td>TB - Completed (previously treated DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>AAiHWXynwMP</td>
        <td>TB - Completed (new and relapse pulmonary bacteriologically confirmed DS-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>RgcWLiawMTQ</td>
        <td>TB - Completed (all DS-TB/HIV cases) (%)</td>
    </tr>
    <tr>
        <td>Indicator</td>
        <td>L6TXyCTI2mW</td>
        <td>TB - Completed (all DR-TB cases) (%)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>b8BvZ2yyAGI</td>
        <td>TBc_1.2a_New smear positive by age group and sex (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>NpBI7jrzA0z</td>
        <td>TBc_1.3a_New cases (all forms) by age group (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>zvXhppFsdjd</td>
        <td>TBc_1.3b_New smear positive cases by age group (0-14 group) (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>cT3HLHVOOwF</td>
        <td>TBc_4.3a_Treatment outcomes for DS-TB/HIV (%)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>q9Tag5rbuDJ</td>
        <td>TBc_4.3a_Treatment outcomes for DS-TB/HIV (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>A3sd6M0Ar3A</td>
        <td>TBc_4.3b_Treatment outcomes for previously treated DS-TB (%)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>UHn8QRtiKGH</td>
        <td>TBc_4.3b_Treatment outcomes for previously treated DS-TB (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>Fw0CsA5Dpvf</td>
        <td>TBc_4.3c_Treatment outcomes for DR-TB (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>qjAxCdXK4it</td>
        <td>TBc_4.3d_Treatment outcomes for bacteriologically confirmed DS-TB (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>ORUu9PBi84b</td>
        <td>TBc_4.3e_Treatment outcomes for smear positive DS-TB (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>ztsp2Ew6kdN</td>
        <td>TBc_6.2a_TB/HIV cascade of care (all cases)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>gOYlLJb51tn</td>
        <td>TBc_6.2a_TB/HIV cascade of care (all cases) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>BSKSZRKbSUU</td>
        <td>TBc_6.2b_TB/HIV cascade of care (%)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>dXIKcGcRfC4</td>
        <td>TBc_6.2b_TB/HIV cascade of care (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>cS2kUPAkWri</td>
        <td>TBc_6.2c_TB/HIV cascade of care (all cases) (%)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>qmmhMtrCtby</td>
        <td>TBc_6.2c_TB/HIV cascade of care (all cases) (%) (annual)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>obyjcDqxXls</td>
        <td>TBc_6.3a_TB/HIV – all TB cases (%)</td>
    </tr>
    <tr>
        <td>Chart</td>
        <td>xpiCsSSLVXp</td>
        <td>TBc_6.3a_TB/HIV – all TB cases (%) (annual)</td>
    </tr>
    <tr>
        <td>Map</td>
        <td>R2kLLio5dEv</td>
        <td>TBm_6.1a_All TB cases with known HIV status in 2017 (%) (annual)</td>
    </tr>
    <tr>
        <td>Map</td>
        <td>ICV9ugEX8hT</td>
        <td>TBm_6.1a_All TB cases with known HIV status in 2017Q4 (%)</td>
    </tr>
</table>

